Tag debug info: client: {"assets":{},"datasets":{},"live":{},"projects":{},"users":{},"observable":{"assets":{},"datasets":{},"live":{},"projects":{},"users":{}}} Now: 1770483291485 Cache Key: cqdTagPageBySlug:diffuse-large-b-cell-lymphoma fetchCache[cqdTagPageBySlug:diffuse-large-b-cell-lymphoma].expirationTime: falsey fetchCache[cqdTagPageBySlug:diffuse-large-b-cell-lymphoma]. seconds remaining: falsey All fetchCache expiration times: -- Key: cqdNotFoundPage, seconds remaining: 8522 -- Key: cqdTagPageBySlug:capsular-contracture, seconds remaining: -1855 -- Key: cqdPostsByTag:cqd-migrated-tag-20509,1,10, seconds remaining: -1784 -- Key: cqdTagPageBySlug:accreditation, seconds remaining: -390 -- Key: cqdPostsByTag:cqd-migrated-tag-21165,1,10, seconds remaining: -309 -- Key: cqdTagPageBySlug:endemic, seconds remaining: -111 -- Key: cqdPostsByTag:cqd-migrated-tag-24323,1,10, seconds remaining: -40 -- Key: cqdTagPageBySlug:chelation-therapy, seconds remaining: 672 -- Key: cqdPostsByTag:cqd-migrated-tag-24310,1,10, seconds remaining: 743 -- Key: cqdTagPageBySlug:overwhelm, seconds remaining: 2331 -- Key: cqdPostsByTag:cqd-migrated-tag-17151,1,10, seconds remaining: 2397 -- Key: cqdTagPageBySlug:ulcerative-colitis, seconds remaining: 3519 -- Key: cqdPostsByTag:cqd-migrated-tag-715,1,10, seconds remaining: 3595 -- Key: cqdTagPageBySlug:michael-maier, seconds remaining: 4299 -- Key: cqdPostsByTag:cqd-migrated-tag-729,1,10, seconds remaining: 4447 -- Key: cqdTagPageBySlug:staffing-models, seconds remaining: 4753 -- Key: cqdPostsByTag:cqd-migrated-tag-17882,1,10, seconds remaining: 4819 -- Key: cqdTagPageBySlug:endoleak, seconds remaining: 5030 -- Key: cqdPostsByTag:cqd-migrated-tag-21864,1,10, seconds remaining: 5109 -- Key: cqdTagPageBySlug:apoe, seconds remaining: 5336 -- Key: cqdPostsByTag:cqd-migrated-tag-17570,1,10, seconds remaining: 5397 -- Key: cqdTagPageBySlug:mechanical-ventilation, seconds remaining: 7183 -- Key: cqdPostsByTag:cqd-migrated-tag-5088,1,10, seconds remaining: 7256 -- Key: cqdTagPageBySlug:debridement, seconds remaining: 7504 -- Key: cqdPostsByTag:cqd-migrated-tag-23949,1,10, seconds remaining: 7571 -- Key: cqdTagPageBySlug:hepsin, seconds remaining: 8056 -- Key: cqdPostsByTag:cqd-migrated-tag-22395,1,10, seconds remaining: 8130 -- Key: cqdTagPageBySlug:john-suh, seconds remaining: 8522 -- Key: cqdPostsByTag:cqd-migrated-tag-749,1,10, seconds remaining: 8609 conditions: -- false, -- NA, -- NA, -- NA -- false Cache miss for key cqdTagPageBySlug:diffuse-large-b-cell-lymphoma - retrieving from Sanity CCCache.dataFetchCount: 11559 Cache cleanup seconds remaining: 18145
Advertisement
Advertisement
Tag: diffuse large b-cell lymphoma
Age alone should not rule out patients from potentially curative treatment
Study measures real-world outcomes for relapsed or refractory large B-cell lymphoma
Optimized responses in transplant- and CAR T-cell therapy-eligible patients
CAR T-cell therapy, bispecifics and antibody drug conjugates have changed disease management
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Cleveland Clinic Cancer Institute takes multi-faceted approach to ensuring clinical trials representation
Dispelling myths and sharing practical experiences
Distinct molecular features found in five subtypes of disease
Patients who relapse early after first-line chemotherapy are often, but not always, refractory to second-line chemotherapy
A New Standard of Care in Relapsed/Refractory Large B-Cell Lymphoma
Improving safety, efficacy and access for emerging therapies
Rendered: Sat Feb 07 2026 16:54:51 GMT+0000 (Coordinated Universal Time)
9500 Euclid Avenue, Cleveland, Ohio 44195 |
800.223.2273 | ©
2026 Cleveland Clinic. All Rights Reserved.
Search
